Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

COX2 inhibitor

DRUG CLASS:

COX2 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Basal Cell Carcinoma	No biomarker	Basal Cell Carcinoma	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2
No biomarker	Squamous Cell Skin Cancer	No biomarker	Squamous Cell Skin Cancer	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2	celecoxib Resistant: A2 - Guideline celecoxib Resistant : A2
No biomarker	Colon Cancer	No biomarker	Colon Cancer	amlodipine/celecoxib Resistant: B - Late Trials amlodipine / celecoxib Resistant : B	amlodipine/celecoxib Resistant: B - Late Trials amlodipine / celecoxib Resistant : B
MSI-H/dMMR	Colorectal Cancer	MSI-H/dMMR	Colorectal Cancer	toripalimab-tpzi + DRGT-46 Sensitive: C3 – Early Trials toripalimab-tpzi + DRGT-46 Sensitive : C3	toripalimab-tpzi + DRGT-46 Sensitive: C3 – Early Trials toripalimab-tpzi + DRGT-46 Sensitive : C3
PIK3CA mutation	Head and Neck Cancer	PIK3CA mutation	Head and Neck Cancer	celecoxib Sensitive: D – Preclinical celecoxib Sensitive : D	celecoxib Sensitive: D – Preclinical celecoxib Sensitive : D
HER-2 positive	HER2 Positive Breast Cancer	HER-2 positive	HER2 Positive Breast Cancer	parecoxib Sensitive: D – Preclinical parecoxib Sensitive : D	parecoxib Sensitive: D – Preclinical parecoxib Sensitive : D